Careers Media center Contacts

Arterium Corporation has expanded its blood sugar lowering drug Gliptar

Arterium Corporation has expanded its blood sugar lowering drug Gliptar

4 September 2018 | News

Gliptar helps prevent hyperglycaemia and weight gain in diabetes patients, also preserving and restoring the function of insulin-producing β cells. Besides, it may be prescribed in combination with other drugs. For instance, it may prove indispensable in the case of contraindications and intolerance to first-line drugs (specifically metformin, thiazolidinedione, sulfonylurea) or insufficient therapeutic effect thereof. Gliptar blocks the glucagon-raising enzyme and thereby normalizes metabolic processes instead of boosting insulin secretion that ultimately exhausts the pancreas. The drug has a good tolerability profile and causes no gastrointestinal disturbance, so it may be administered to patients with moderate kidney and liver dysfunction.

Production is handled by Kievmedpreparat.

         *Arterium Corporation—Arterium Corporation itself and its parts OJSC Kievmedpreparat and OJSC Galychpharm. This information is intended for medical and pharmaceutical personnel only and shall be used only in relevant professional activities. The data given here is abridged. For full information about the medicinal product, refer to its instructions for medical use. This website is a specialised publication intended for medical and pharmaceutical personnel only.

Media gallery
PRESS KIT

Here you can find general information about the company intended for journalists and other stakeholders

MEDIA CONTACTS

For all media-related enquiries,
please contact us
e-mail: pr@arterium.ua
mob.: +38050 446 71 20, +38095 278 92 80